Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22024527 | 1.00 | HRH4 (0.36) | HRH4HSD11B1KCNN3LMNAMAPT | |
| SCHEMBL19953341 | 0.83 | LMNA (0.44) | HRH4HSD11B1KCNN3LMNAMAPT | |
| SCHEMBL29598922 | 0.83 | LMNA (0.44) | HRH4HSD11B1KCNN3LMNAMAPT | |
| SCHEMBL30503534 | 0.83 | KDM4E (0.41) | HRH4HSD11B1KCNN3LMNA | |
| SCHEMBL26631311 | 0.83 | KDM4E (0.41) | HRH4HSD11B1KCNN3LMNA | |
| SCHEMBL30503520 | 0.81 | HRH4 (0.34) | HRH4 | |
| SCHEMBL26105826 | 0.81 | HRH4 (0.34) | HRH4 | |
| SCHEMBL30540477 | 0.78 | PIM1 (0.44) | HRH4LMNAMAPT | |
| SCHEMBL30611847 | 0.78 | CYP2A6 (0.36) | HRH4MAPT | |
| SCHEMBL30611921 | 0.78 | HRH4 (0.32) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119585252-A | Bicyclic heteroaryl containing compounds as IKZF2 degrading agents | 翁科皮亚治疗公司和SK生命科学实验室 | 2025-03-07 | — | — | CN | disclosed |
| EP-4499629-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-114667167-B | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2023183919-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4010080-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2022-06-15 | — | — | EP | disclosed |